BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its first quarter 2026 financial results on Friday, May 1, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.

BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations totaling $2 million to multiple patient assistance foundations supporting individuals living with Parkinson's disease (PD) in recognition of Parkinson's Awareness Month.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has earned a consensus recommendation of "Buy" from the seven brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The

SG Americas Securities LLC boosted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) by 2,866.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 784,803 shares of the company's stock after purchasing an additional 758,343 shares during

The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to ​update their prescribing information with a new warning about ‌a potential risk of seizures.

Amneal Pharmaceuticals, Inc. remains a Buy, with 45-55% upside potential and a $5-6bn market cap target in my opinion. AMRX delivered strong 2025 results—revenue up to $3.02bn, operating income $421m, and net leverage reduced to 3.5x. 2026 guidance is mixed: 1-4% revenue growth, but 5-10% adjusted EBITDA and 12-24% EPS growth, with division performance diverging.

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

ECG, AMRX, NESR, ACMR and HSY have been added to the Zacks Rank #1 (Strong Buy) List on March 9th, 2026.

AMRX, VET and NESR made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 9th, 2026.

BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside chat at the following upcoming investor conference: